Items Tagged ‘blincyto’

June 23rd, 2016

Blincyto® Improves Survival in Type of Acute Lymphoblastic Leukemia

By

The immunotherapeutic agent, Blincyto (blinatumomab), improves survival compared to standard therapy among patients with B-cell precursor, Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (BCP-ALL) that has stopped responding to prior therapies. These results were presented at a presidential symposium at the 2016 annual European Hematologic Association (EHA) meeting. Acute lymphoblastic leukemia (ALL) is the most aggressive […]

View full entry

Tags: 2016, Acute Lymphoblastic Leukemia, all, BCP-ALL, blinatumomab, blincyto, EAH, Leukemia, News, TOWER trial


January 19th, 2016

Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

By

Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in […]

View full entry

Tags: Acute Lymphoblastic Leukemia, acute lymphoblastic lymphoma, all, blincyto, cd19, immunotherapy, Leukemia, News, Philadelphia chromosome positive


July 23rd, 2015

Blincyto® in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Appears Promising

By

Biotechnology company Amgen has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, amgen, blinatumomab, blincyto, Leukemia, News


May 19th, 2015

Blincyto®

By

Class: Biological Therapy Generic Name: Blinatumomab Trade Name: Blincyto® For which conditions is this drug approved? Blincyto is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute ALL. What is the mechanism of action? Blincyto is a type of drug known as a monoclonal […]

View full entry

Tags: Acute Lymphoblastic Leukemia, B, Biological Therapy, blincyto, Drug Dictionary


May 19th, 2015

Blinatumomab

By

Class: Biological Therapy Generic Name: Blinatumomab Trade Name: Blincyto® For which conditions is this drug approved? Blincyto is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute ALL. What is the mechanism of action? Blincyto is a type of drug known as a monoclonal […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, B, Biological Therapy, blincyto, Drug Dictionary